8/104 sources · 3 publishersUpdated Nov 16, 20:49 UTC
Rapid Micro Biosystems posts Q3 results and announces acquisition by Merck KGaA
Rapid Micro Biosystems reported third‑quarter 2026 revenue of about $9.5 million, a 21.6% year‑over‑year increase, and a record gross margin of 25.2%. The company posted a GAAP net loss of $11.268 million and an adjusted EBITDA loss of $7.944 million. It also signed a definitive agreement to be acquired by Merck KGaA, after which it withdrew its full‑year 2026 guidance.
Why it matters
The acquisition will transfer control of Rapid Micro to Merck KGaA and may accelerate adoption of the Growth Direct platform. Withdrawal of full‑year guidance removes a forward‑looking benchmark for investors.
Key facts
- 1Q3 2026 revenue was $9.528 million, up 21.6% from the same quarter a year earlier. tradingview.com
- 2Gross margin for the quarter was 25.2%, a record for the company. tradingview.com
- 3GAAP net loss amounted to $11.268 million, or $0.23 per share. tradingview.com
- 4Non‑GAAP adjusted EBITDA loss narrowed to $7.944 million. tradingview.com
- 5Rapid Micro signed a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany. tradingview.com
- 6The company withdrew its full‑year 2026 guidance following the acquisition announcement. tradingview.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.